$98.79
1.97% yesterday
Nasdaq, Jun 13, 10:16 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Stock price

$98.73
+33.02 50.25% 1M
+27.10 37.83% 6M
+29.69 43.00% YTD
+37.10 60.20% 1Y
+70.34 247.76% 5Y
+75.71 328.89% 10Y
+89.13 928.44% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+1.85 1.91%
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Key metrics

Market capitalization $17.65b
Enterprise Value $17.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 46.13
P/S ratio (TTM) P/S ratio 46.31
P/B ratio (TTM) P/B ratio 177.73
Revenue growth (TTM) Revenue growth 20.77%
Revenue (TTM) Revenue $381.03m
EBIT (operating result TTM) EBIT $-859.01m
Free Cash Flow (TTM) Free Cash Flow $-789.25m
Cash position $1.20b
EPS (TTM) EPS $-5.60
P/E forward negative
P/S forward 38.07
EV/Sales forward 37.93
Short interest 10.80%
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

Buy
100%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
381 381
21% 21%
100%
- Direct Costs 90 90
29% 29%
24%
291 291
18% 18%
76%
- Selling and Administrative Expenses 516 516
44% 44%
135%
- Research and Development Expense 630 630
12% 12%
165%
-854 -854
26% 26%
-224%
- Depreciation and Amortization 5.05 5.05
0% 0%
1%
EBIT (Operating Income) EBIT -859 -859
26% 26%
-225%
Net Profit -1,013 -1,013
36% 36%
-266%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Neutral
PRNewsWire
2 days ago
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share.
Neutral
PRNewsWire
2 days ago
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering.
Neutral
Seeking Alpha
3 days ago
Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to reach $12.2 billion by 2032. Brensocatib's NDA for bronchiectasis is under Priority Review, with a PDUFA date of August 12, 2025, targeting an untapped market.
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 1,271
Founded 1988
Website insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today